EP3665196
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
8.8.2018EP published:
19.10.2022EP application number:
18755421.7
EPO information:
European Patent Register
Max expiry date:
7.8.2038
Title in English:
OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUPLanguage of the patent:
English
Timeline
Today
8.8.2018EP application
19.10.2022EP Publication
Owner
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, 4070 Basel, CH
Name:
NanoString Technologies, Inc.Address:
530 Fairview Ave North, Seattle, WA 98109, US
Inventor
Name:
OESTERGAARD, Mikkel ZahleAddress:
8702 Zollikon, CH
Priority
Number:
201762542489 PDate:
8.8.2017Country:
US
Classification
Categories:
C07K 16/28, A61K 39/395